Cannabis Law Report
JULY 20, 2021
The creation of this standalone cannabis department is part of a larger effort to improve access to licensure, simplify regulatory oversight and support California businesses. Salama was Assistant Branch Chief of the California Department of Public Health’s Manufactured Cannabis Safety Branch. Chief Deputy Director – Rasha Salama.
Cannabis Law Report
JUNE 28, 2021
Thomas wrote that a 2005 Supreme Court ruling – Gonzales v. Specifically, Thomas referred to legislation passed by Congress every year since 2015 prohibiting the Justice Department from interfering in states’ medical cannabis access programs. to define criminal law and to protect the health, safety, and welfare of their citizens.’
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Greencamp
APRIL 23, 2019
Multiple sclerosis qualifies one for getting access to medical cannabis in some states in the US. In 2005, a group of researchers was looking into the effectiveness and long-term safety of tetrahydrocannabinol for MS. In Canada, patients suffering from MS are eligible for becoming medical cannabis users.
Cannabis Law Report
SEPTEMBER 12, 2021
I was appointed to the NCUA in 2005 under President Bush and served a four-year term that ended in 2009. We’re talking here primarily about taking deposits, opening up lending at reasonable rates of interest, and opening increased access to payment systems so you don’t have to handle massive piles of cash. Thank you.
CannaMD
DECEMBER 9, 2020
The AHA position paper then moves on to address a range of known, potential, and suggested safety concerns associated with cannabis use. Thirdly, the statement notes that there are currently no “well documented” cardiovascular benefits of cannabis. ACUTE EFFECTS OF MARIJUANA.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. Refractory paediatric epilepsy.
The Cannigma
JUNE 29, 2021
Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using. But from a clinical perspective, we know almost nothing about this type of cannabis — either about its safety or its efficacy. Type V: Zero cannabinoids.
Expert insights. Personalized for you.
105 
Let's personalize your content